Clinical trial · Interventional
Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer
F18 NaF PET/CT and Whole Body and Axial MRI for the Detection of Metastases in Patients With Biochemical Recurrence of Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This phase II trial studies how well fluorine F 18 sodium fluoride positron emission tomography (PET)/computed tomography (CT) and whole body and axial magnetic resonance imaging (MRI) work in finding metastases in patients with recurrent prostate cancer. New imaging techniques, such as fluorine F 18 sodium fluoride PET/CT and whole body and axial MRI, may be more effective than standard CT and bone scan in finding metastatic prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Prostate Cancer | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3-Tesla magnetic resonance imaging | Procedure | — | UNRESOLVED |
| bone scan | Procedure | — | UNRESOLVED |
| computed tomography | Procedure | — | UNRESOLVED |
| diffusion-weighted magnetic resonance imaging | Procedure | — | UNRESOLVED |
| fluorine F 18 sodium fluoride | Radiation | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| positron emission tomography | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic (CT, bone scan, WB/axial MRI, F18 NaF PET/CT)
- description
- Patients first undergo CT scan and bone scan. Patients with negative results from the CT and bone scans then undergo WB MRI scan using diffusion-weighted MRI, axial MRI scan using 3-Tesla MRI, and fluorine F 18 sodium fluoride PET/CT scan.
- interventionNames
- Procedure: computed tomography
- Procedure: bone scan
- Procedure: 3-Tesla magnetic resonance imaging
- Procedure: diffusion-weighted magnetic resonance imaging
- Radiation: fluorine F 18 sodium fluoride
- Procedure: positron emission tomography
- Other: laboratory biomarker analysis
Primary outcomes (1)
- measure
- Number of Eligible Patients With Positive CT Scan/Bone Scan, MRI and PET Scan.
- timeFrame
- Up to 12 months
- description
- Count of eligible patients with positive CT chest, abdomen, pelvis scan, positive WB/axial MRI, positive F-18 NaF PET/CT and positive Bone scan for detection of metastatic disease.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * History of prior radical prostatectomy for prostate cancer * Two PSA values \>= 0.2 ng/mL at least 4 weeks after prostatectomy * Patients who have started radiographic evaluation and underwent CT scan and/or bone scan prior to registration to the study will be able to participate under a late registration provision, provided that the more modern scans (WB/axial MRI and F-18 NaF PET/CT) can be completed within 8 weeks after CT scan and bone scan Exclusion Criteria: * Patients with known metastatic disease * PSA recurrence not verified by elevated PSA as discussed in the eligibility section * Patients who initiated androgen deprivation therapy or other systemic therapy (chemotherapy, immunotherapy, targeted therapy) for PSA recurrence; nutritional supplements used for treatment of PSA recurrence will be allowed
References
Publications (0)
Data not yet available